FasL gene therapy: A new therapeutic modality for head and neck cancer

Cancer Gene Therapy

Volumn 13, Issue 8, 2006, Pages 739-745

  ElOjeimy, S ^a   McKillop, J C ^a   El Zawahry, A M ^a   Holman, D H ^a   Liu, X ^a   Schwartz, D A ^a   Day, T A ^a   Dong, J Y ^a   Norris, J S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adenovirus; Apoptosis; Fas ligand; Gene therapy; Head and neck cancer

Indexed keywords

CASPASE 9; FAS ANTIGEN; FAS LIGAND; FAS MONOCLONAL ANTIBODY CH 11; GREEN FLUORESCENT PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TETRAZOLIUM; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER REGRESSION; CELL DEATH; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME DEGRADATION; FLOW CYTOMETRY; HEAD AND NECK CARCINOMA; HUMAN; MOUSE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; BYSTANDER EFFECT; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FAS LIGAND PROTEIN; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEAD AND NECK NEOPLASMS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; TUMOR NECROSIS FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; MURINAE;

EID: 33746257318     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700951     Document Type: Article

References (23)

1. Ferris RL. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed? ORL 2004; 66: 332-340.
2. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806-816.
3. Norris JS, Norris KL, Holman DH, El-Zawahry A, Keane TE, Dong JY et al. The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Med 2004; 1: 1-9.
4. Suda T, Nagata S. Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994; 3: 873-879.
5. Takahashi T, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S et al. Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol 1994; 10: 1567-1574.
6. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 6: 1169-1178.
7. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997; 12: 2045-2050.
8. Gulbins E, Bissonnette R, Mahboubi A, Martin S, Nishioka W, Brunner T et al. FAS-induced apoptosis is mediated via a ceramideinitiated RAS signaling pathway. Immunity 1995; 4: 341-351.
9. Ambar BB, Frei K, Malipiero U, Morelli AE, Castro MG, Lowenstein PR et al. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther 1999; 10: 1641-1648.
10. Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB et al. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ 1999; 6: 175-182.
11. Zhang SW, Xiao SW, Liu CQ, Sun Y, Su X, Li DM et al. Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 cases. Zhonghua Yi Xue Za Zhi 2003; 23: 2023-2028.
12. Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol Ther 2000; 2: 348-358.
13. Harrington KJ, Nutting CM, Pandha HS. Gene therapy for head and neck cancer. Cancer Metastasis Rev 2005; 1: 147-164.
14. Hyer ML, Sudarshan S, Schwartz DA, Hannun YA, Dong J-Y, Norris JS. Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther 2003; 10: 330-339.
15. Rubinchik S, Morris JS, Dong JY. Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes. Methods Enzymol 2002; 346: 529-547.
16. Hyer ML, Sudarshan S, Kim Y, Reed JC, Dong JY, Schwartz DA et al. Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to fas-mediated apoptosis. Cancer Biol Ther 2002; 1: 401-406.
17. Sudarshan S, Holman DH, Hyer ML, Norris JS. In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther 2005; 12: 12-18.
18. Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist 2005; 1: 215-224.
19. Day TA, Davis BK, Gillespie MB, Joe JK, Kibbey M, Martin-Harris B et al. Oral cancer treatment. Curr Treat Opt Oncol 2003; 1: 27-41.
20. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 2005; 11: 160-172.
21. Nemunaitis J, O'Brien J. Head and neck cancer: gene therapy approaches. Part II: genes delivered. Expert Opin Biol Ther 2002; 3: 311-324.
22. Maecker HL, Yun Z, Maecker HT, Giaccia AJ. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2002; 2: 139-148.
23. Norris JS, Holman DH, Hyer ML, Bielawska A, El-Zawahry A, Chalfant C et al. Ceramide, ceramidase and FasL gene therapy in prostate cancer. In: El-Deiry WS (ed). Death Receptors in Cancer Therapy. Humana Press Inc.: Totowa, NJ, 2004, pp 323-338.